RedHill Biopharma (RDHL) Long-Term Deferred Tax (2017)

RedHill Biopharma (RDHL) reported Long-Term Deferred Tax of $76.0 million for Q4 2017.

RedHill Biopharma (RDHL) Long-Term Deferred Tax (2017) Analysis & Trends

RedHill Biopharma (RDHL) has 1 years of Long-Term Deferred Tax data on file, last reported at $76.0 million in Q4 2017.

  • Long-Term Deferred Tax for Q4 2017 came in at $76.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was $76.0 million (changed N/A YoY), and the FY2017 annual result was $76.0 million, changed N/A from the prior year.
  • Long-Term Deferred Tax was little changed at $76.0 million in Q4 2017 per RDHL's latest filing.
  • Over five years, Long-Term Deferred Tax peaked at $76.0 million in Q4 2017 and troughed at $76.0 million in Q4 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn
10 RedHill Biopharma 142.34 Mn 142.34 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2017 76.00 Mn